nach oben

Erschienen in:

01.05.2009 | Original Article

Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer

verfasst von: M. Graeser, K. Bosse, M. Brosig, C. Engel, R. K. Schmutzler, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer

Erschienen in: Virchows Archiv | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

BRCA1-associated breast cancer frequently presents with estrogen-receptor (ERα) and progesterone-receptor (PR) negativity, grade 3, and early onset. In contrast, in BRCA1-deficient mice, ERα is highly expressed in early tumorigenesis. In a retrospective cohort study on 587 breast cancer patients with deleterious BRCA1 mutations, the correlation of ER, PR status, grading, age of onset, and tumor size was investigated. ERα and PR expression decreased from 62% in ductal carcinoma in situ (DCIS) to 20% and 16% in pT3, respectively (p value for ER 0.025 and PR 0.035, Fisher’s exact test). The percentage of grade 1/2 tumors decreased from 44% in DCIS to 17% in pT3 (p value 0.074). Moreover, ER/PR positivity increased with increasing age. Our data suggest that early stage BRCA1-associated breast cancers are more frequently ERα and PR positive and low grade than advanced stages.

Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689PubMedCrossRef

Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343:692–695PubMedCrossRef

Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRef

Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4:814–819PubMedCrossRef

Fan S, Wang J, Yuan R et al (1999) BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284:1354–1356PubMedCrossRef

Razandi M, Pedram A, Rosen EM et al (2004) BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol 4:5900–5913CrossRef

Korach KS (1994) Insights from the study of animals lacking functional estrogen receptor. Science 266:1524–1527PubMedCrossRef

Li X, Lonard DM, O'Malley BW (2004) A contemporary understanding of progesterone receptor function. Mech Ageing Dev 125:669–678PubMedCrossRef

Ma Y, Katiyar P, Jones LP et al (2006) The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol 20:14–34PubMedCrossRef

10.

Zheng L, Annab LA, Afshari CA et al (2001) BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci USA 98:9587–9592PubMedCrossRef

11.

Li W, Xiao C, Vonderhaar BK et al (2007) A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation. Oncogene 26:7204–7212PubMedCrossRef

12.

Johannsson OT, Idvall I, Anderson C et al (1997) Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33:362–371PubMedCrossRef

13.

Eisinger F, Jacquemier J, Nogues C et al (1999) Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1585:2291–2295CrossRef

14.

Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRef

15.

Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876–1881PubMedCrossRef

16.

King TA, Gemignani ML, Li W et al (2004) Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. Cancer Res 64:5051–5053PubMedCrossRef

17.

Poole AJ, Li Y, Kim Y et al (2006) Prevention of BRCA1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314:1467–1470PubMedCrossRef

18.

Meindl A (2002) Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97:472–480PubMedCrossRef

19.

Remmele W, Schicketanz KH (1993) Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 189:862–866PubMed

20.

Atchley DP, Albarracin CT, Lopez A et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 1026:4282–4288CrossRef

21.

Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034PubMedCrossRef

22.

Vaziri SA, Krumroy LM, Elson P et al (2001) Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 7:1937–1945PubMed

23.

Metcalfe K, Lynch HT, Ghadirian P et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328–2335PubMedCrossRef

24.

Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRef

25.

Jones LP, Li M, Halama ED et al (2005) Promotion of mammary cancer development by tamoxifen in a mouse model of BRCA1-mutation-related breast cancer. Oncogene 24:3554–3562PubMedCrossRef

Titel: Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer
verfasst von: M. Graeser
K. Bosse
M. Brosig
C. Engel
R. K. Schmutzler
on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer
Publikationsdatum: 01.05.2009
Verlag: Springer-Verlag
Erschienen in: Virchows Archiv / Ausgabe 5/2009
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-009-0760-8

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2009

Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology

Intraosseous lymphocytic infiltrates after hip resurfacing arthroplasty

Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density

Biliary intraductal papillary mucinous neoplasia: three case reports

Diagnosis of autoimmune pancreatitis by core needle biopsy: application of six microscopic criteria

Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien